



Prevalence of the eosinophilic phenotype among severe asthma patients in Brazil: the BRAEOS study

Rodrigo Athanzio¹, Rafael Stelmach¹, Martti Antila²,
 Adelmir Souza-Machado³, L. Karla Arruda⁴, Alcindo Cerci Neto⁵,
 Faradiba Sarquis Serpa⁶, Daniela Cavalet Blanco⁷, Marina Lima⁸,
 Pedro Bianchi Júnior⁹, Márcio Penha¹⁰, Marcelo Fouad Rabahi¹¹

Table S1. Characteristics of the study participants and comorbidities in the sample as a whole and by chronic oral corticosteroid use.

Characteristic	Total (N = 387)	C-OCS users (n = 14)	C-OCS nonusers (n = 373)	p
Age, years				
Median (IQR)	54.0 (19.0-93.0)	56.0 (34.0-72.0)	53.0 (19.0-93.0)	0.3902
Sex, n (%)				
Female	304 (78.6)	10 (71.4)	294 (78.8)	0.5150
Male	83 (21.4)	4 (28.6)	79 (21.2)	
BMI (kg/m ²)				
Median	29.0 (14.9-49.0)	31.8 (24.3-44.8)	28.7 (14.9-49.0)	0.0735
Moderate asthma exacerbations (in the previous 12 months)				
0 exacerbations	103 (26.7)	1 (7.1)	102 (27.4)	0.0639
1 exacerbation	70 (18.1)	1 (7.1)	69 (18.5)	
2 exacerbations	71 (18.4)	2 (14.3)	69 (18.5)	
≥ 3 exacerbations	142 (36.8)	10 (71.4)	132 (35.5)	
Severe asthma exacerbations (in the previous 12 months)				
0 exacerbations	370 (95.6)	11 (78.6)	359 (96.2)	0.0164
1 exacerbation	13 (3.4)	2 (14.3)	11 (2.9)	
2 exacerbations	2 (0.5)	0 (0.0)	2 (0.5)	
≥ 3 exacerbations	2 (0.5)	1 (7.1)	1 (0.3)	
Overall exacerbation rate (in the previous 12 months)	2.8	10.7	2.5	
Moderate exacerbation rate (in the previous 12 months)	2.7	10.3	2.4	
Severe exacerbation rate (in the previous 12 months)	0.1	0.4	0.06	
History of atopy	313 (81.7)	10 (71.4)	303 (82.1)	0.2975
Comorbidities				
Rhinitis	329 (85.0)	12 (85.7)	317 (85.0)	> 0.9999
Gastroesophageal reflux	199 (51.4)	7 (50.0)	192 (51.5)	0.9137
Obesity	173 (44.7)	9 (64.3)	164 (44.0)	0.1333
Hypertension	123 (31.8)	7 (50.0)	116 (31.1)	0.1503
Anxiety	92 (23.8)	6 (42.9)	86 (23.1)	0.1081
Depression	76 (19.6)	5 (35.7)	71 (19.0)	0.1624
Osteoporosis	54 (14.0)	2 (14.3)	52 (13.9)	> 0.9999
Type 2 diabetes	50 (12.9)	2 (14.3)	48 (12.9)	0.6995
Atopic dermatitis	39 (10.1)	2 (14.3)	37 (9.9)	0.6414
Nasal polyps	35 (9.0)	2 (14.3)	33 (8.8)	0.3667
Sleep apnea	25 (6.5)	2 (14.3)	23 (6.2)	0.2266
Cataract	23 (5.9)	0 (0.0)	23 (6.2)	> 0.9999
Vocal cord dysfunction	19 (4.9)	0 (0.0)	19 (5.1)	> 0.9999
History of stroke	9 (2.3)	2 (14.3)	7 (1.9)	0.0379
Coronary artery disease	9 (2.3)	1 (7.1)	8 (2.1)	0.2848
Heart failure	9 (2.3)	2 (14.3)	7 (1.9)	0.0379
None	6 (1.6)	0 (0.0)	6 (1.6)	> 0.9999
Charlson Comorbidity Index				
Median (IQR)	1.0 (0.0-8.0)	2.0 (0.0-4.0)	1.0 (0.0-8.0)	0.4625

C-OCS: chronic oral corticosteroid.




Figure S1. Comorbidities in patients with the eosinophilic phenotype of severe asthma.^a

^aTo calculate the predicted values of pulmonary function variables, we used the equations published by Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. *J Bras Pneumol.* 2007;33(4):397-406. <https://doi.org/10.1590/S1806-37132007000400008>